|
2024 Journal Article Material Trends and Clinical Costings in Systematically Identified CDER‐Approved NanomedicinesJarrett, Thomas Ryan, Pregelj, Lisette, Bell, Craig Andrew, Fletcher, Nicholas Lyle and Thurecht, Kristofer James (2024). Material Trends and Clinical Costings in Systematically Identified CDER‐Approved Nanomedicines. Advanced Therapeutics, 7 (10) 2400124. doi: 10.1002/adtp.202400124 |
|
2024 Journal Article Anticipatory regulation for pandemic responses: are we there yet?Oyola-Lozada, Maria Giuliana, Pregelj, Lisette, Jenkins, Anna, Siegel, Evan, Munro, Trent and Hine, Damian (2024). Anticipatory regulation for pandemic responses: are we there yet?. Trends in Biotechnology, 42 (9), 1067-1071. doi: 10.1016/j.tibtech.2024.02.016 |
|
2024 Journal Article Are manufacturing patents to blame for biosimilar market launch delays?Williamson, Rhys, Munro, Trent, Ascher, David, Robertson, Avril and Pregelj, Lisette (2024). Are manufacturing patents to blame for biosimilar market launch delays?. Value in Health, 27 (3), 287-293. doi: 10.1016/j.jval.2023.12.005 |
|
2023 Journal Article Delivering impactful solutions for the bioeconomyHankamer, Ben, Pregelj, Lisette, O’Kane, Shane, Hussey, Karen and Hine, Damian (2023). Delivering impactful solutions for the bioeconomy. Trends in Plant Science, 28 (5), 583-596. doi: 10.1016/j.tplants.2023.02.007 |
|
2023 Journal Article Restoring Australia’s long-term innovation requires investment in basic researchHarrison, Rosemary S., Barnard, Ross T. and Pregelj, Lisette (2023). Restoring Australia’s long-term innovation requires investment in basic research. Microbiology Australia, 44 (1), 57-61. doi: 10.1071/ma23014 |
|
2022 Other Outputs InterviewsOyola Lozada, Giuliana, Jenkins, Anna, Pregelj, Lisette and MacAulay, Sam (2022). Interviews. The University of Queensland. (Dataset) doi: 10.48610/4ef737d |
|
2021 Journal Article Assessing the Impact of US Food and Drug Administration Breakthrough Therapy designation timing on trial characteristics and development speedPregelj, Lisette, Hine, Damian C., Kesselheim, Aaron S. and Darrow, Jonathan J. (2021). Assessing the Impact of US Food and Drug Administration Breakthrough Therapy designation timing on trial characteristics and development speed. Clinical Pharmacology and Therapeutics, 110 (4) cpt.2318, 1018-1024. doi: 10.1002/cpt.2318 |
|
2021 Other Outputs Adaptive regulation for digital health: enhancing Australia’s regulation systemStephens, Anna, Pregelj, Lisette, Hine, Damian and Smith, Alexander (2021). Adaptive regulation for digital health: enhancing Australia’s regulation system. Brighton, VIC, Australia: MTPConnect. |
|
2020 Journal Article Working hard or hardly working? Regulatory bottlenecks in developing a COVID-19 vaccinePregelj, Lisette, Hine, Damian C., Oyola-Lozada, Maria G. and Munro, Trent P. (2020). Working hard or hardly working? Regulatory bottlenecks in developing a COVID-19 vaccine. Trends in Biotechnology, 38 (9), 943-947. doi: 10.1016/j.tibtech.2020.06.004 |
|
2018 Conference Publication Trading-off innovation speed for knowledge during drug developmentPregelj, Lisette, Hine, Damian Charles, Becerra, Manuel and Verreynne, Martie-Louise (2018). Trading-off innovation speed for knowledge during drug development. Academy of Management Annual Meeting, Chicago, IL United States, 10-14 August 2018. Briarcliff Manor, NY United States: Academy of Management. doi: 10.5465/ambpp.2018.15704abstract |
|
2018 Journal Article Precision medicines have faster approvals based on fewer and smaller trials than other medicinesPregelj, Lisette, Hwang, Thomas J., Hine, Damian C., Siegel, Evan B., Barnard, Ross T., Darrow, Jonathan J. and Kesselheim, Aaron S. (2018). Precision medicines have faster approvals based on fewer and smaller trials than other medicines. Health affairs (Project Hope), 37 (5), 724-731. doi: 10.1377/hlthaff.2017.1580 |
|
2018 Book Chapter Commercializing university research to mitigate simultaneous change stimuli: an exemplar case from the Australian higher education sectorHine, Damian, Pregelj, Lisette and McManus, Michael (2018). Commercializing university research to mitigate simultaneous change stimuli: an exemplar case from the Australian higher education sector. World scientific reference on innovation. (pp. 97-112) edited by Donald Siegel. Singapore: World Scientific . doi: 10.1142/9789813149045_0006 |
|
2015 Journal Article Changes in clinical trial lengthPregelj, Lisette, Verreynne, Martie-Louise and Hine, Damian (2015). Changes in clinical trial length. Nature Reviews Drug Discovery, 14 (5), 307-308. doi: 10.1038/nrd4611 |
|
2013 Journal Article Deconstructing and reconstructing the capability hierarchyHine, Damian, Parker, Rachel, Pregelj, Lisette and Verreynne, Martie-Louise (2013). Deconstructing and reconstructing the capability hierarchy. Industrial and Corporate Change, 23 (5), 1299-1325. doi: 10.1093/icc/dtt046 |
|
2013 Other Outputs Capability development along the capability lifecycle: Evidence from the pharmaceutical industryPregelj, Lisette (2013). Capability development along the capability lifecycle: Evidence from the pharmaceutical industry. PhD Thesis, UQ Business School, The University of Queensland. |
|
2012 Other Outputs Brisbane Innovation Scorecard 2012. Brisbane City Council and Brisbane Marketing Economic Development BoardSteen, John, Verreynne, Martie-Louise, Pregelj, Lisette, Foster, Mishka and Cretchley, Julia (2012). Brisbane Innovation Scorecard 2012. Brisbane City Council and Brisbane Marketing Economic Development Board. Brisbane, Australia: Brisbane Marketing. |
|
2011 Journal Article Transcription profiling of the isoflavone phenylpropanoid pathway in soybean in response to Bradyrhizobium japonicum inoculationPregelj, Lisette, McLanders, Joanne R., Gresshoff, Peter M. and Schenk, Peer M. (2011). Transcription profiling of the isoflavone phenylpropanoid pathway in soybean in response to Bradyrhizobium japonicum inoculation. Functional Plant Biology, 38 (1), 13-24. doi: 10.1071/FP10093 |
|
2011 Book Chapter Small pharmaceutical firms building capabilities to compete along the global research and development pipelinePregelj, Lisette, Verreynne, Martie-Louise and Hine, Damian (2011). Small pharmaceutical firms building capabilities to compete along the global research and development pipeline. International entrepreneurship in the life sciences. (pp. 64-100) edited by Marian V. Jones, Colin Wheeler and Pavlos Dimitratos. Cheltenham United Kingdom: Edward Elgar Publishing. |
|
2011 Conference Publication Capability development in the pharmaceutical commercialisation processPregelj, Lisette, Verreynne, Martie-Louise and Hine, Damian (2011). Capability development in the pharmaceutical commercialisation process. 14th Asia-Pacific Researchers in Organization Studies Conference (APROS 2011), Auckland, New Zealand, 28 November - 1 December 2011. Auckland, New Zealand: Auckland University of Technology. |
|
2010 Conference Publication Capability building in the pharmaceutical industryHine, D., Pregelj, L. and Verreynne, M. (2010). Capability building in the pharmaceutical industry. Strategic Management Society Conference, Rome, Italy, 12-15 September, 2010. |
